Moderna (MRNA) reports Q1 earnings May 1 premarket—see consensus EPS (-$3.96), revenue ($236M), and estimate revisions to ...
StockStory.org on MSN
Moderna (MRNA) reports earnings tomorrow: What to expect
Biotechnology company Moderna (NASDAQ:MRNA) will be reporting results this Friday morning. Here’s what you need to know.
Moderna Inc. (NASDAQ:MRNA) is one of the best performing S&P 500 stocks so far in 2026. On April 21, the European Commission ...
Investors may be wondering whether Moderna's current share price reflects its true value, or if the market is still trying to ...
Cancer cocktails pairing Moderna’s mRNA-4359 with Merck’s Keytruda and Marengo’s invikafusp alfa with Gilead Sciences’ ...
Moderna (NasdaqGS:MRNA) plans to present Phase 1/2 data for its mRNA-4359 cancer antigen therapy combined with pembrolizumab ...
The U.S. helped pioneer the technology, but new funding cuts may shift breakthroughs — and industry leadership — overseas.
Moderna initiated a large clinical trial of an mRNA vaccine for bird flu, despite delays due to HHS funding cuts.
COMBRIAX is the world's first flu plus COVID combination vaccine to receive marketing authorization and Moderna's ...
The US Food and Drug Administration has refused to accept an application from Moderna to review its first mRNA seasonal flu vaccine, the company said Tuesday, in another setback for the technology ...
This week, the European Commission authorized Moderna to market the vaccine, mRNA-1083 or mCOMBRIAX, making it the world’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results